Regarding abatacept, a small retrospective Japanese study reported no significant differences in the incidence of adverse events between younger and elderly RA patients (≥75 years), while the overall retention rate of CTLA4-Ig and infection-free survival were similar in the two groups. This evidence concerns the gene CTLA4 and rheumatoid arthritis.